Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.

Eliciting broadly neutralizing antibodies (bnAb) in cervicovaginal mucus (CVM) represents a promising "first line of defense" strategy to reduce vaginal HIV transmission. However, it remains unclear what levels of bnAb must be present in CVM to effectively reduce infection. We approached t...

Full description

Bibliographic Details
Main Authors: Scott A McKinley, Alex Chen, Feng Shi, Simi Wang, Peter J Mucha, M Gregory Forest, Samuel K Lai
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4072659?pdf=render
_version_ 1818404728699092992
author Scott A McKinley
Alex Chen
Feng Shi
Simi Wang
Peter J Mucha
M Gregory Forest
Samuel K Lai
author_facet Scott A McKinley
Alex Chen
Feng Shi
Simi Wang
Peter J Mucha
M Gregory Forest
Samuel K Lai
author_sort Scott A McKinley
collection DOAJ
description Eliciting broadly neutralizing antibodies (bnAb) in cervicovaginal mucus (CVM) represents a promising "first line of defense" strategy to reduce vaginal HIV transmission. However, it remains unclear what levels of bnAb must be present in CVM to effectively reduce infection. We approached this complex question by modeling the dynamic tally of bnAb coverage on HIV. This analysis introduces a critical, timescale-dependent competition: to protect, bnAb must accumulate at sufficient stoichiometry to neutralize HIV faster than virions penetrate CVM and reach target cells. We developed a model that incorporates concentrations and diffusivities of HIV and bnAb in semen and CVM, kinetic rates for binding (kon) and unbinding (koff) of select bnAb, and physiologically relevant thicknesses of CVM and semen layers. Comprehensive model simulations lead to robust conclusions about neutralization kinetics in CVM. First, due to the limited time virions in semen need to penetrate CVM, substantially greater bnAb concentrations than in vitro estimates must be present in CVM to neutralize HIV. Second, the model predicts that bnAb with more rapid kon, almost independent of koff, should offer greater neutralization potency in vivo. These findings suggest the fastest arriving virions at target cells present the greatest likelihood of infection. It also implies the marked improvements in in vitro neutralization potency of many recently discovered bnAb may not translate to comparable reduction in the bnAb dose needed to confer protection against initial vaginal infections. Our modeling framework offers a valuable tool to gaining quantitative insights into the dynamics of mucosal immunity against HIV and other infectious diseases.
first_indexed 2024-12-14T08:44:46Z
format Article
id doaj.art-334bb602899c4bd484c7f215d456b7ab
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-14T08:44:46Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-334bb602899c4bd484c7f215d456b7ab2022-12-21T23:09:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e10059810.1371/journal.pone.0100598Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.Scott A McKinleyAlex ChenFeng ShiSimi WangPeter J MuchaM Gregory ForestSamuel K LaiEliciting broadly neutralizing antibodies (bnAb) in cervicovaginal mucus (CVM) represents a promising "first line of defense" strategy to reduce vaginal HIV transmission. However, it remains unclear what levels of bnAb must be present in CVM to effectively reduce infection. We approached this complex question by modeling the dynamic tally of bnAb coverage on HIV. This analysis introduces a critical, timescale-dependent competition: to protect, bnAb must accumulate at sufficient stoichiometry to neutralize HIV faster than virions penetrate CVM and reach target cells. We developed a model that incorporates concentrations and diffusivities of HIV and bnAb in semen and CVM, kinetic rates for binding (kon) and unbinding (koff) of select bnAb, and physiologically relevant thicknesses of CVM and semen layers. Comprehensive model simulations lead to robust conclusions about neutralization kinetics in CVM. First, due to the limited time virions in semen need to penetrate CVM, substantially greater bnAb concentrations than in vitro estimates must be present in CVM to neutralize HIV. Second, the model predicts that bnAb with more rapid kon, almost independent of koff, should offer greater neutralization potency in vivo. These findings suggest the fastest arriving virions at target cells present the greatest likelihood of infection. It also implies the marked improvements in in vitro neutralization potency of many recently discovered bnAb may not translate to comparable reduction in the bnAb dose needed to confer protection against initial vaginal infections. Our modeling framework offers a valuable tool to gaining quantitative insights into the dynamics of mucosal immunity against HIV and other infectious diseases.http://europepmc.org/articles/PMC4072659?pdf=render
spellingShingle Scott A McKinley
Alex Chen
Feng Shi
Simi Wang
Peter J Mucha
M Gregory Forest
Samuel K Lai
Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.
PLoS ONE
title Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.
title_full Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.
title_fullStr Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.
title_full_unstemmed Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.
title_short Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa.
title_sort modeling neutralization kinetics of hiv by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa
url http://europepmc.org/articles/PMC4072659?pdf=render
work_keys_str_mv AT scottamckinley modelingneutralizationkineticsofhivbybroadlyneutralizingmonoclonalantibodiesingenitalsecretionscoatingthecervicovaginalmucosa
AT alexchen modelingneutralizationkineticsofhivbybroadlyneutralizingmonoclonalantibodiesingenitalsecretionscoatingthecervicovaginalmucosa
AT fengshi modelingneutralizationkineticsofhivbybroadlyneutralizingmonoclonalantibodiesingenitalsecretionscoatingthecervicovaginalmucosa
AT simiwang modelingneutralizationkineticsofhivbybroadlyneutralizingmonoclonalantibodiesingenitalsecretionscoatingthecervicovaginalmucosa
AT peterjmucha modelingneutralizationkineticsofhivbybroadlyneutralizingmonoclonalantibodiesingenitalsecretionscoatingthecervicovaginalmucosa
AT mgregoryforest modelingneutralizationkineticsofhivbybroadlyneutralizingmonoclonalantibodiesingenitalsecretionscoatingthecervicovaginalmucosa
AT samuelklai modelingneutralizationkineticsofhivbybroadlyneutralizingmonoclonalantibodiesingenitalsecretionscoatingthecervicovaginalmucosa